• Testing the Valuation of the EQ-5D-Y-5L in Adults and Adolescents: Results From a 5-Country Study and Implications for the Descriptive System

    Dec 1, 2025, 00:00

  • P9 Exploring Variability in EQ VAS Scores: A Systematic Review and Meta-Regression of Population Health Studies

    Dec 1, 2025, 00:00

  • HTA334 The Uptake of R in NICE HTA: Insights From Technology Assessment Groups

    Dec 1, 2025, 00:00

  • RWD135 Persistence With Osteoporosis Medication Treatments Among Chinese Patients With Osteoporosis: A Retrospective Cohort Study

    Dec 1, 2025, 00:00

  • HSD48 Evaluation of the Article 51 VIGIE-AGE Experiment: A Significant Impact on Hospitalizations Resulting in Reduced Total Expenditure

    Dec 1, 2025, 00:00

  • MT2 Adoption of AI Clinical Decision Support Systems in Primary Care: An Evaluation of Physician Acceptance

    Dec 1, 2025, 00:00

  • MSR32 Applying the Delphi Method: A Scoping Review in Healthcare Decision Making and HEOR

    Dec 1, 2025, 00:00

  • PCR256 Unseen Burdens of Glycogen Storage Disease Type Ia (GSDIa) Experienced by Patients, Caregivers, and their Healthcare Team

    Dec 1, 2025, 00:00

  • EPH223 Survey of Depression Literacy and Help-Seeking Behavior Among Secondary School Students

    Dec 1, 2025, 00:00

  • P28 Survival Time-Adjusted Indirect Comparisons: A New Methodology for Comparing Between Phases of Treatment in Early Cancer

    Dec 1, 2025, 00:00

  • SA76 Pragmatic Advice to Improve Assessment Schedule of Preference-Based Measures of Health to Estimate Utilities in Clinical Trials

    Dec 1, 2025, 00:00

  • CO67 Current Methodological Practices to Define Within-Patient Meaningful Change in Rare Diseases: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • PCR118 Health-Related Quality of Life in Patients With Metastatic Urothelial Cancer: Results of a Cross-Sectional Survey in Europe

    Dec 1, 2025, 00:00

  • EPH58 Detection of a Potential Pericarditis Safety Signal Associated With Azithromycin: Evidence From FAERS Disproportionality Analysis

    Dec 1, 2025, 00:00

  • MSR221 What Is the Value of Large Language Models for Improving Extraction and Interpretation of Efficiency Data From French Commission Dévaluation Économique et de Santé Publique (CEESP): Decisions on Breast Cancer Medications?

    Dec 1, 2025, 00:00

  • MSR26 An Update on the Evolving Use of Artificial intelligence and Machine Learning (AI/ML) in Systematic Literature Reviews (SLRs)

    Dec 1, 2025, 00:00

  • CO214 Robotic-Assisted Surgery Using the Da Vinci Surgical System in a Nordic Population: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • CO216 Safety and Efficacy of Antibody Drug Conjugate (ADCs) in Pretreated Locally Advanced/Metastatic (LA/m) Triple-Negative Breast Cancer (TNBC): Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • MSR9 A Retrieval-Augmented Generation (RAG)-Based Framework to Automate Report Writing for Systematic Literature Reviews (SLRs) in Evidence Synthesis

    Dec 1, 2025, 00:00

  • EE708 The Five-Year Budget Impact of Introducing Semaglutide 2.4 mg for Obesity Management in Saudi Arabia: A Real-World Patient Flow and Complication-Driven Model

    Dec 1, 2025, 00:00

  • HTA221 Life-Cycle Stage-Specific Prioritization of Joint Clinical Assessment PICOs: Balancing Access Potential Feasibility and Likelihood

    Dec 1, 2025, 00:00

  • EPH67 Economic and Epidemiological Burden of Type 1 Diabetes In France

    Dec 1, 2025, 00:00

  • HPR9 A Review of the UK's International Recognition Procedure and Its Role in Expediting Access to Innovative Treatments

    Dec 1, 2025, 00:00

  • PT22 Advanced Therapy Medicinal Products From Promise to Practi Understanding Reimbursement and Access Disparities in Western Europe

    Dec 1, 2025, 00:00

  • EE311 Cost-Utility Analysis of Transcatheter Valve Replacement Using Valves With RESILIA Tissue for the Treatment of Aortic Stenosis in South Korea

    Dec 1, 2025, 00:00

  • OP25 Understanding the Needs and Aspirations of Emerging HEOR Talent: Results From the ISPOR New Professional and Student Survey

    Dec 1, 2025, 00:00

  • EE509 Healthcare Resource Utilization (HCRU) and Associated Costs in Patients With Advanced Merkel Cell Carcinoma (aMCC) in Germany: Analysis From the MCC TRIM Registry Study

    Dec 1, 2025, 00:00

  • EE345 Early Adoption of New Combination Biologic Therapy Enabled by Enhanced Diagnostic Accuracy in Inflammatory Bowel Disease (IBD) Can Be a Budget-Neutral Approach: A Budget Impact Analysis in Italy

    Dec 1, 2025, 00:00

  • EE516 Healthcare Resource Utilization and Time Burden in Patients With Myelodysplastic Syndromes/Neoplasms Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents

    Dec 1, 2025, 00:00

  • MSR80 Economic Valuation of Premature COVID-19 Mortality in Kuwait: A Comparative Analysis of Three Methodological Approaches

    Dec 1, 2025, 00:00

  • PCR42 Characterizing the UK Population Living With Von Willebrand Disease: Foundational Data for Health Economics and Outcomes Research

    Dec 1, 2025, 00:00

  • EE429 Estimation of Utility Weights for Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Previously Treated with a Covalent Bruton Kinase Inhibitor (cBTKi)

    Dec 1, 2025, 00:00

  • EE424 Estimating the Clinical and Economic Value of Aztreonam-Avibactam for the Treatment of Metallo-Beta-Lactamase–Producing Carbapenem- Resistant Enterobacterales Infections in China: Adopting the STEDI Value Framework

    Dec 1, 2025, 00:00

  • HPR188 Solving the PICO Puzzle: Perspectives on Outcome Measures for Oncology Medicines in Assessments of the European Medicines Agency and Health Technology Assessment Organizations in Europe

    Dec 1, 2025, 00:00

  • CO5 A Systematic Review and Network Meta Analysis of Pharmacologic Disease-Modifying Therapies for Early Alzheimer's Disease

    Dec 1, 2025, 00:00

  • EE194 Cost-Effectiveness Analysis of Cariprazine vs. Risperidone for the Treatment of Schizophrenia With Predominantly Negative Symptoms (PNS) in United Arab Emirates

    Dec 1, 2025, 00:00

  • EE656 Site of Care Cost-Effectiveness of Axicabtagene Ciloleucel in Relapsed/Refractory Second-Line or Later Large B-cell Lymphoma in the United States: Analyses for Inpatient and Outpatient Infusion Settings

    Dec 1, 2025, 00:00

  • HPR43 Characterizing Medicines Reimbursed Under Managed Access Protocols in Ireland (2006-2025)

    Dec 1, 2025, 00:00

  • CO4 A Systematic Review (SR) and Network Meta-Analysis (NMA) of Cystic Fibrosis Transmembrane Conductance Receptor (CFTR) Modulator Therapies and Established Clinical Management (ECM) Using Percent Predicted Forced Expiratory Volume in One ...

    Dec 1, 2025, 00:00

  • CO6 Addressing Clinical Uncertainties in ATMP Reimbursement: A Review of European Methodological Guidelines and Practices

    Dec 1, 2025, 00:00

  • HSD78 Optimizing Healthcare Access Through Policy Innovation: An Implementation Evaluation Framework for Hepatitis C Elimination Program in Malaysia

    Dec 1, 2025, 00:00

  • CO250 Therapeutic Benefit of Radiotherapy in Uterine Serous Carcinoma (USC): A Real-World Study

    Dec 1, 2025, 00:00

  • EPH265 Tropical Virus in Fran Dengue Cases on the Rise

    Dec 1, 2025, 00:00

  • MSR79 Early Detection of Cancer Therapy-Related Cardiac Dysfunction in Lung Cancer Patients Using Machine Learning

    Dec 1, 2025, 00:00

  • PCR89 Exploration of the Utility of Linguistic Validation Cognitive Debriefing Interviews in Generating Evidence for Adding or Modifying Source COA Content

    Dec 1, 2025, 00:00

  • HTA312 The 90-Day Ambition: Historical Analysis of 200 NICE Appraisals to Assess Proportion-Achieving Final Guidance Within 90 Days of MHRA Approval

    Dec 1, 2025, 00:00

  • RWD102 Improving Identification of Patients With Rare Diseases Through Indirect Linkage Between French Medico-Administrative Claims Database (SNDS) and National Rare Disease Registry (BNDMR) in Fran A Dual-Population Study

    Dec 1, 2025, 00:00

  • EE22 A Model-Based Analysis of the Impact on Labor Market Supply From Enhanced Tobacco Control Strategies in Denmark

    Dec 1, 2025, 00:00

  • HSD61 Impact on Prescribing Choice Following the Identification of Preferred Continuous Glucose Monitoring Sensors in the Irish Healthcare Setting

    Dec 1, 2025, 00:00

  • EPH33 Burden of Bloodstream Infections in the United States: Incidence and Healthcare Resource Utilization 2022-2024

    Dec 1, 2025, 00:00

  • OP23 Streamlining Cancer Treatment Pathways: Organizational Responses to Rising Chemotherapy Volumes

    Dec 1, 2025, 00:00

  • RWD14 AI-Assisted Expert Computable Operation Definition (CODef) Development for Real-World Research

    Dec 1, 2025, 00:00

  • EE257 Cost-Effectiveness of In-Hospital Motivational Smoking Cessation Counseling and Proactive Referral to Primary Care Follow-up

    Dec 1, 2025, 00:00

  • RWD172 Sex Differences in Characteristics and Treatment Patterns of Patients With Sleep Disorders in South Korea

    Dec 1, 2025, 00:00

  • HTA124 Enhancing Patient Involvement in European Health Technology Assessment (HTA): From Inconsistent National Practices to Systematic Engagement in Joint Clinical Assessments

    Dec 1, 2025, 00:00

  • HTA58 Bridging the Uncertainty: Cancer Drugs Fund Entry and Exit Outcomes Over Three Years

    Dec 1, 2025, 00:00

  • MSR148 Missing Health State Utility Values (HSUV) in NICE Oncology Appraisals: A Systematic Review of Utility Data Reporting and Handling Practices

    Dec 1, 2025, 00:00

  • EE177 Cost of Adverse Events With the Bruton Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib in the First-Line Treatment of Chronic Lymphocytic Leukemia in Brazil

    Dec 1, 2025, 00:00

  • EE590 Modeling Treatment-Free Remission Outcomes for Asciminib in Newly Diagnosed Chronic Myeloid Leukemia: Assumptions, Methodology, and Projections

    Dec 1, 2025, 00:00

  • EPH248 The Incidence, Mortality, and Survival of Metastatic Colorectal Cancer (CRC) per TNM Stages in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2018-2022 Database Analysis

    Dec 1, 2025, 00:00

  • HTA259 One Trial, Two Clocks: Coordinating EMA Assessment and Complementary EU HTA Evidence

    Dec 1, 2025, 00:00

  • HSD38 Economic Burden and Healthcare Resource Utilization of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Germany: A Claims Data Analysis

    Dec 1, 2025, 00:00

  • MSR179 Reducing the Rare Disease Diagnostic Odyssey: Identifying Potential Pulmonary Arterial Hypertension Patients Using the Problem List of Diagnosed Patients

    Dec 1, 2025, 00:00

  • HTA40 Are We There Yet? Mapping Member State Readiness for Local Implementation of the EU Health Technology Assessment (HTA) Regulation

    Dec 1, 2025, 00:00

  • HPR144 Narrative Review of Total Quality-Adjusted Life Year (QALY) Gains From Oncology Medicines Reimbursed From 2020 To 2025 in Ireland

    Dec 1, 2025, 00:00

  • PT10 An Analysis of Possible Reference Countries for a US Most-Favored Nation Policy and the Associated Impact on the Global Pharmaceutical Industry

    Dec 1, 2025, 00:00

  • EE718 The Ongoing Challenge of Clostridioides Difficile Infection in Austria: Economic Evaluation of Two Recommended Treatment Pathways

    Dec 1, 2025, 00:00

  • PCR155 Measuring Quality of Life in Huntington’s Disease Using a Proxy Approach: Validation of the HD-mQoL-prx Measure

    Dec 1, 2025, 00:00

  • EE187 Cost Savings From Patient Preference-Based Allocation of High-Efficacy Therapies for MS: Evidence From Switzerland

    Dec 1, 2025, 00:00

  • PCR160 Mental Health Benefits of Exercise Variation: Evidence From the 2024 5EU National Health and Wellness Survey

    Dec 1, 2025, 00:00

  • CO98 Epidemiological Study of Pulmonary Hypertension in Patients With Interstitial Lung Diseases (PH-ILD) in Gree A Retrospective Multicenter Study

    Dec 1, 2025, 00:00

  • HPR28 Are We Getting Good Value for Innovative Therapies in the US? Findings From Generalized Cost-Effectiveness Analyses (GCEAs)

    Dec 1, 2025, 00:00

  • EE197 Cost-Effectiveness Analysis of Entrectinib in First-Line Treatment for NTRK Locally Advanced or Metastatic NSCLC in China

    Dec 1, 2025, 00:00

  • EE265 Cost-Effectiveness of Pegcetacoplan for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in Patients With Treatment Failure After C5 Inhibitor Therapy: An Analysis From the Brazilian Public Healthcare System Perspective

    Dec 1, 2025, 00:00

  • RWD24 Association of Recurrences With Healthcare Resource Utilization in High-Risk Non-Muscle Invasive Bladder Cancer Patients Across Europe: A Real-World Survey

    Dec 1, 2025, 00:00

  • MSR212 Use of a Nonparametric Bayesian Method to Model Health State Preferences: An Application to UAE EQ-5D-5L Valuations

    Dec 1, 2025, 00:00

  • EE329 Digital Health Literacy, Engagement, and the Economics of Health Behavior: Evidence from the US HINTS Survey

    Dec 1, 2025, 00:00

  • HTA330 The Role of Health-Related Quality of Life in German HTA Decisions: An Analysis of G-BA Assessments From 2020-2024

    Dec 1, 2025, 00:00

  • HPR125 Innovative Drug Access in Portugal: An Analysis of Managed Entry Agreements Supporting Public Coverage 2014-2024

    Dec 1, 2025, 00:00

  • HTA311 Targeted Review of mITT vs. ITT Data in CAR-T Submissions

    Dec 1, 2025, 00:00

  • EE3 A Budget Impact Analysis of Switching From Von Willebrand Factor/Factor VIII Plasma-Derived Concentrate With 2.4-1 Ratio to the Concentrate With 1-1 Ratio for the Management of Von Willebrand Disease in Qatar

    Dec 1, 2025, 00:00

  • HPR217 Three Systems, One Market? A Comparative Analysis of Medical Device Reimbursement in Germany, Austria, and Switzerland

    Dec 1, 2025, 00:00

  • HTA9 A Matching-Adjusted Indirect Comparison (MAIC) of Rucaparib vs. Niraparib in the Maintenance Treatment of Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer (aOC) After Response to First-Line Platinum-Based Chemotherapy

    Dec 1, 2025, 00:00

  • EPH269 Unlocking Insights in Prescription Data in England: The Power of the Prescribing Episode Statistics (PES) Database

    Dec 1, 2025, 00:00

  • HTA354 Validation of a Natural Language Processing Solution (REALLI) Compared to Manual Review by Physicians of Electronic Health Records (EHR) From Patients With HER2+ Metastatic Breast Cancer

    Dec 1, 2025, 00:00

  • EE209 Cost-Effectiveness Analysis of Isavuconazole vs. Liposomal Amphotericin B for the Treatment of Invasive Mucormycosis in Morocco

    Dec 1, 2025, 00:00

  • PCR141 Integrating PROMs Into Real-World Ophthalmology Practi A Pilot Project on Neovascular AMD

    Dec 1, 2025, 00:00

  • HPR24 Analysis of Historical European Medicines Agency (EMA) Marketing Authorization (MA) Timelines: Will EU Joint Clinical Assessment (JCA) Timelines Be Longer Than Expected?

    Dec 1, 2025, 00:00

  • HPR141 Melatonin Use Among Children and Adolescents: A Finnish Nationwide Drug Utilization Study

    Dec 1, 2025, 00:00

  • CO215 Roflumilast Foam 0.3% in Patients With Psoriasis of the Scalp and Body: Improvements in Patient-Reported Outcomes and Quality of Life

    Dec 1, 2025, 00:00

  • CO159 Lipid-Lowering Prescription Patterns After a Nonfatal Acute Coronary Syndrome: The Impact of Real-World Evidence on Clinical Practice With LATINO-ACS 2.0

    Dec 1, 2025, 00:00

  • P63 No Strong Preference? Acceptance of the Quantitative Incorporation of Patient Preference in Economic Modeling in Past NICE Technology Appraisals

    Dec 1, 2025, 00:00

  • EE616 Pricing Implications of Subcutaneous Reformulations Following Intravenous Launches: A Multicountry Analysis

    Dec 1, 2025, 00:00

  • MSR6 A Multistate Framework for Analyzing Outcomes in Diffuse Large B-cell Lymphoma With Autologous Hematopoietic Stem Cell Transplant

    Dec 1, 2025, 00:00

  • EE221 Cost-Effectiveness Analysis of the Prostate Health Index (PHI) Test After a Prostate-Specific Antigen (PSA) Test in UK

    Dec 1, 2025, 00:00

  • EPH242 The Importance and Recognition of Hypo and Hyperkalemia in Prehospital Care

    Dec 1, 2025, 00:00

  • HPR202 The Impact of Annual Price Revision Based on External Reference Pricing on Medicines Between 2012 and 2023 in Portugal

    Dec 1, 2025, 00:00

  • CO162 Matching-Adjusted Indirect Comparison Between Garadacimab and Donidalorsen for Long-Term Prophylaxis in Hereditary Angioedema

    Dec 1, 2025, 00:00

  • HPR170 Real-World Data for External Controls: Insights From EMA Regulatory Submissions

    Dec 1, 2025, 00:00

  • EE450 Evolving Payer Preferences for Health Economic Information and Communication in the US

    Dec 1, 2025, 00:00

  • EPH48 Comorbidities and Comedication Among Individuals in Treatment for ADHD: A Danish Nationwide Study

    Dec 1, 2025, 00:00

  • EE595 Obstructive Sleep Apnea (OSA) Phenotypes and the Personalized Impact of Positive Airway Pressure (PAP) Therapy on Healthcare Resource Use

    Dec 1, 2025, 00:00

  • CO194 Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Prevention of Respiratory Syncytial Virus Illness Among High-Risk Adults Aged 18-59 Years in Germany

    Dec 1, 2025, 00:00

  • EE45 An Early Cost-Effectiveness Model for a Digital Community-Based Approach for Streamlined Audiology Care

    Dec 1, 2025, 00:00

  • EE462 Feasibility Evaluation of Claims Database: Best Practices and Case Study for a Comparative Analysis of Robotic-Assisted Colorectal Surgery in Germany

    Dec 1, 2025, 00:00

  • EE315 Cost Utility of Subcutaneous Methotrexate As a Second-Line Treatment for Moderate to Severe Rheumatoid Arthritis in the UK

    Dec 1, 2025, 00:00

  • HSD23 Characteristics of DNAR Orders Among Non-Critically Ill Extremely Elderly Patients Admitted to a University Hospital in Japan

    Dec 1, 2025, 00:00

  • HPR25 Analysis of the Impact of the TelE-Medicine Program for Medically Underserved Area on Hospitalization Rates Among Diabetic Patients in Medically Underserved Areas

    Dec 1, 2025, 00:00

  • CO182 Postmarketing Safety Analysis of Nebivolol in Real-World Settings Using Bioinformatics and Disproportionality Analysis With FDA Adverse Event Reporting System (FAERS) Data

    Dec 1, 2025, 00:00

  • MSR121 How Does the Source of Transition Probabilities Influence Natural History Simulation and Economic Evaluation in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?

    Dec 1, 2025, 00:00

  • CO140 Impact of Pharmacotherapy Adherence on the Reduction of Major Adverse Cardiovascular Events (MACE) Among Atherosclerotic Cardiovascular Disease (ASCVD) Patients

    Dec 1, 2025, 00:00

  • HSD123 Value-Based Decision Making in a Social Security Provider in Argentina for Oncology and Oncohematology Drugs

    Dec 1, 2025, 00:00

  • EE582 Model Behavior: A Health Economics Checklist for Sales Models

    Dec 1, 2025, 00:00

  • P31 Comparative Performance of the EQ-5D-5L and PROMIS-10 in the Elderly: Data From the EQ-DAPHNIE Project in Five Countries

    Dec 1, 2025, 00:00

  • EPH197 Public Health and Economic Impact of RSVpreF Vaccination Among Older Adults in Latin America and the Caribbean

    Dec 1, 2025, 00:00

  • EE272 Cost-Effectiveness of rhTNK-tPA vs. rt-PA for Acute Ischemic Stroke Patients Within 4.5H of Symptom Onset in China

    Dec 1, 2025, 00:00

  • EE518 Healthcare Resource Utilization in Patients With Non-Small Cell Lung Cancer (NSCLC) and Epidermal Growth Factor Receptor Mutation (eGFRm): A Retrospective Cohort Study in a Portuguese Comprehensive Cancer Center

    Dec 1, 2025, 00:00

  • PT35 Cost-Effectiveness Analysis of Ribociclib Plus Endocrine Therapy for the Treatment of HR/HER2 Early Breast Cancer in Greece

    Dec 1, 2025, 00:00

  • CO128 Health Technology Assessment, Reimbursement, and Funding Landscape Challenges for Oncology Companion Diagnostics in Europe and Canada

    Dec 1, 2025, 00:00

  • HSD59 How the NHS Can Optimize Health Outcomes in a Time of Financial Constraint

    Dec 1, 2025, 00:00

  • HTA239 Multicriteria Health Technology Assessments for High-Cost Oncology Drugs in Peru: A Cross-Sectional Study of RENETSA Records 2023-2024

    Dec 1, 2025, 00:00

  • HSD22 Characteristics and Treatment of Prevalent Heart Failure in the US: A Cross-Sectional Analysis of Annual Trends From 2014-2023

    Dec 1, 2025, 00:00

  • EPH69 Effectiveness of HPV Vaccination Across Europe: A Comparative Analysis

    Dec 1, 2025, 00:00

  • HTA281 Recent Changes in HTA and Reimbursement Requirements: Learnings for Global Dossiers

    Dec 1, 2025, 00:00

  • HSD45 Ethical Implications of the Use of Artificial Intelligence (AI) Based Technologies for Medical Image Classification Systems in Screening: A Qualitative Systematic Review

    Dec 1, 2025, 00:00

  • EPH256 The Use of Multiple Sleep Medications Is Highly Prevalent

    Dec 1, 2025, 00:00

  • EE412 Enhancing Palliative Care in Intensive Care Units (EPIC) Trial Design of the Health Economic Substudy

    Dec 1, 2025, 00:00

  • EE196 Cost-Effectiveness Analysis of Dostarlimab Plus Carboplatin-Paclitaxel in Primary Advanced or Recurrent Endometrial Cancer With Deficient Mismatch Repair (dMMR) and High Microsatellite Instability (MSI-H) in France

    Dec 1, 2025, 00:00

  • MSR191 Survival Extrapolations With and Without Incorporating External Eviden Evaluating the Performance of Bayesian M-Spline Models vs. Parametric Models in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    Dec 1, 2025, 00:00

  • HTA8 A Long and Winding Road: An Evaluation of NICE HST Appraisals Taking Longer Than Two Years for Guidance Publication

    Dec 1, 2025, 00:00

  • EE122 CAR-NK Cell Therapy for Ovarian Cancer Treatment in the First Relapse: Assessing Conditions Needed for Cost-Effectiveness in the Netherlands Using Early Health-Economic Modeling

    Dec 1, 2025, 00:00

  • MSR158 Optimizing MASLD Follow-up Strategies Under Adherence Uncertainty: A Game Theory and Signaling Approach

    Dec 1, 2025, 00:00

  • MSR100 Evaluation of the Use of ChatGPT in Data Extraction for Systematic Literature Reviews: Friend, Foe, or Fiction?

    Dec 1, 2025, 00:00

  • HTA30 An Irish Retrospective Analysis of Oncology Reimbursement Applications Considered by HSE Drugs Group 2022-2024

    Dec 1, 2025, 00:00

  • EPH172 Objective Real-World Caregiver Costs and Lost Time for Absences and Family Medical Leaves in the United States for Employees Whose Spouses Have Dementia and/or Alzheimer’s Disease and Patient Direct Costs

    Dec 1, 2025, 00:00

  • EE619 Productivity Losses Due to Ill Health Among Adults Aged 50 and Older in Greece

    Dec 1, 2025, 00:00

  • EPH114 Generating Data for Diversity Planning in Breast Cancer: A Multi-Database Validation Study Using US Claims and HER, Population Census, and Cancer Registry Data in the United States

    Dec 1, 2025, 00:00

  • HSD118 Trends in Receipt of Preventive Healthcare Services from 2020-2024: US Electronic Health Records (EHR) Database Analysis of 118 Million Patients

    Dec 1, 2025, 00:00

  • HPR134 Maintaining Orphan Drug Status at the Time of Drug Approval in European Economic Area (EEA): European Union (EU) Plus Iceland and Norway From 2015 to 2025

    Dec 1, 2025, 00:00

  • EPH134 Impact of Delayed or Missing Diagnosis of Chronic Kidney Disease

    Dec 1, 2025, 00:00

  • EE623 Public Health Impact of Efluelda, a High-Dose Trivalent Influenza Vaccine (TIV-HD) Compared to Standard-Dose Trivalent Inactivated Vaccines (TIV-SD)

    Dec 1, 2025, 00:00

  • EPH203 Real-World Costs of United States Patients With T1 Diabetes, Removing Misdiagnosed Patients, and Compared With Patients With T1D and (T1.5 or T2) Diabetes

    Dec 1, 2025, 00:00

  • HPR194 The Clawbacks Paradox: When Abusing a Simple Approach Has the Most Complicated and Problematic Consequences for Patients and Healthcare Systems

    Dec 1, 2025, 00:00

  • RWD19 Assessing Patient Access to Psoriasis Treatments in Central, South, and Eastern European Countries: Insights and Disparities?

    Dec 1, 2025, 00:00

  • EE199 Cost-Effectiveness Analysis of Follow-up Strategies for Localized or Locally Advanced Renal Cell Carcinoma From the UK NHS Perspective

    Dec 1, 2025, 00:00

  • PCR69 Embedding Patient Experience Data (PED) in EU Joint Clinical Assessments: Strategic Imperatives and Evidence Practices

    Dec 1, 2025, 00:00

  • P5 The Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH) in the US: A Total System Value Evidence Framework

    Dec 1, 2025, 00:00

  • HSD111 Towards Quantifying the Impact of Hypofractionation vs. Standard Radiotherapy Treatment Regimens for Cancer on Costs Workflow and the Environment

    Dec 1, 2025, 00:00

  • MSR202 The Statistical Abyss: Real-World Evidence for Health Technology Assessment

    Dec 1, 2025, 00:00

  • SA46 Get Real: A How-to Framework on Designing and Implementing a Regulatory and HTA-Grade External Comparator Study

    Dec 1, 2025, 00:00

  • EE308 Cost-Utility Analysis of Standard-Dose vs. High-Dose Influenza Vaccination in Adults Aged ≥ 65 Years in Italy

    Dec 1, 2025, 00:00

  • PCR18 Are Discrete Choice Experiment Results Robust to Omitted Attributes? Evidence From a Vaccine Study

    Dec 1, 2025, 00:00

  • PCR200 Qualitative Trial Interviews to Explore the Experience of Adult and Pediatric Patients Participating in a Pivotal Phase 3 Trial of DTX401 for Glycogen Storage Disease Type Ia

    Dec 1, 2025, 00:00

  • P57 Defining "Value" in Digital Health Interventions: A Triangulated Approach to Model Development

    Dec 1, 2025, 00:00

  • HTA290 Revisiting Rarity: Would Yesterday’s NICE Highly Specialized Technologies Still Qualify Today?

    Dec 1, 2025, 00:00

  • EPH230 The Changing Prevalence of Multicomorbid Patients in the US

    Dec 1, 2025, 00:00

  • MSR86 Ensuring Patient Inclusion When Baseline Is Missing: Utilizing Constrained Longitudinal Data Analysis (cLDA) for Patient-Reported Outcomes (PROs)

    Dec 1, 2025, 00:00

  • EE361 Economic Burden of Generalized Myasthenia Gravis (gMG) in Latin America (LA): A Microcosting Analysis of Direct Medical Costs (DMCs)

    Dec 1, 2025, 00:00

  • EE105 Budget Impact of Azathioprine Metabolite Monitoring in Crohn’s Disease in Algeria

    Dec 1, 2025, 00:00

  • HTA368 When Less Is More? Learnings From a Recent NICE Submission Utilizing a Novel Predictive Individual-Level Surrogacy Approach to Predict Overall Survival (OS) in the Absence of Trial-Level Evidence

    Dec 1, 2025, 00:00

  • EE461 Faricimab vs. Aflibercept 8 mg in Patients With Neovascular Age-Related Macular Degeneration: A Cost-Utility Analysis in Italy

    Dec 1, 2025, 00:00

  • MSR17 Agentic-AI Analyzer to Chat With Your Excel-Based Cost-Effectiveness Models

    Dec 1, 2025, 00:00

  • SA65 Matching-Adjusted Indirect Comparisons (MAICs) and Network Meta-Analyses (NMAs) of the Oral Small-Molecule Chaperone Migalastat vs. Intravenous Enzyme Replacement Therapies (ERTs) for Clinical Measures in Fabry Disease

    Dec 1, 2025, 00:00

  • MSR41 Assessing the Psychometric Performance of the Experimental EQ-TIPS V20 in Assessing the Health-Related Quality of Life of Stunted Children in Laos

    Dec 1, 2025, 00:00

  • MSR129 Improving Efficiency in Evidence Synthesis: Performance Assessment of Machine Learning Classifiers for Automated Screening in Systematic Literature Reviews

    Dec 1, 2025, 00:00

  • EE580 Microsimulation Model to Estimate the Clinical and Cost Burden of Adverse Events Related to Long-Term Oral Corticosteroid Usage in Autoimmune Diseases in the United States

    Dec 1, 2025, 00:00

  • EE282 Cost-Minimization Analysis and Economic Impact in EGPA: Evidence From MANDARA

    Dec 1, 2025, 00:00

  • EPH108 Exploring the Impact of Patient Characteristics and Reporting Period on Adverse Drug Withdrawal Event Signals in the FAERS Database: A Stratified Disproportionality Analysis Study

    Dec 1, 2025, 00:00

  • HTA347 Unmet Needs in NICE HTAs: Insights From Obesity and Diabetes Submissions

    Dec 1, 2025, 00:00

  • EPH209 Screening for Chronic Kidney Disease (CKD): A Systematic Review and Meta-Analysis of Trials and Quasi Experimental Studies

    Dec 1, 2025, 00:00

  • HPR112 Health Halo Effect in Supplement Marketing: A Content Analysis of Medical Claims in Community Pharmacies

    Dec 1, 2025, 00:00

  • SA98 Trends in Vaccination at Pharmacies by Race Among Medicaid Recipients: A Claims Analysis

    Dec 1, 2025, 00:00

  • RWD62 Development and Validation of an Automated Cancer Stage Classifier for Real-World Oncology Data Mapped to the OMOP Common Data Model

    Dec 1, 2025, 00:00

  • EPH96 Evidence-Driven Simulated Agents to Train Reinforcement Learning for Personalization in mHealth Interventions

    Dec 1, 2025, 00:00

  • EE427 Estimating the Economic Burden of Potential Chikungunya Outbreaks in Southern Europe

    Dec 1, 2025, 00:00

  • EE511 Healthcare Resource Utilization and Costs Among Bacillus Calmette-Guérin (BCG)-Experienced or Unresponsive Patients With Papillary-Only High-Risk Non–Muscle Invasive Bladder Cancer

    Dec 1, 2025, 00:00

  • HTA82 Comparing HTA Outcomes and Rationale for Decision Making Between Countries With Mature vs. Newly Founded HTA Systems: Evidence From England, France, and Greece

    Dec 1, 2025, 00:00

  • EE592 Multistakeholder Engagement to Codevelop Specifications for Economic Models: The MASH Case Study

    Dec 1, 2025, 00:00

  • SA86 Simulation of the Impact on LDLC Targets and Treatment Cost in High and Very High Cardiovascular Risk Patients of Cost-Based Sequencing of Lipid-Lowering Therapy

    Dec 1, 2025, 00:00

  • PCR129 Impact of Glucagon-Like Peptide-1 Treatments on Patient-Reported Outcomes in Type 2 Diabetes Mellitus

    Dec 1, 2025, 00:00

  • SA26 Current Use of Hereditary Angioedema (HAE) Treatments in Sweden: An Analysis of the National Prescribed Drug Register

    Dec 1, 2025, 00:00

  • PCR73 Enhancing Patient Engagement in Consensus Development: Global Insights From a Targeted Review of Digital Platforms and Methods

    Dec 1, 2025, 00:00

  • CO243 The Impact on Life Expectancy of Delaying or Avoiding Type 1 Diabetes Using the Metabo-Reno-Cardiovascular Disease Model

    Dec 1, 2025, 00:00

  • P23 Optimal Hemoglobin Thresholds for ICU Transfusion: A Target Trial Emulation in a Large Electronic Medical Record-Based Real-World Database

    Dec 1, 2025, 00:00

  • HPR71 Estimating Lost Life-Years and Quality-Adjusted Life-Years of Undertreatment of Patients With Renal Cell Carcinoma and Metastatic Pancreatic Cancer in England

    Dec 1, 2025, 00:00

  • HTA298 Similarities and Differences Between the National Institute for Health and Care Excellence (NICE) and European Union Joint Clinical Assessment (EU JCA) Clinical Systematic Literature Review Requirements

    Dec 1, 2025, 00:00

  • HTA356 Viable Reimbursement and Financing Models for mHealth Interventions in Sub-Saharan Africa: A Narrative Review

    Dec 1, 2025, 00:00

  • HSD9 Assessing the Impact of Technology-Powered, Pharmacy- and Nursing-Supported Direct Oral Anticoagulant Management

    Dec 1, 2025, 00:00

  • EPH151 Is Greece on Track to Meet the 90% HPV Vaccine Coverage Rate Target by 2030? A Mathematical Modeling Study

    Dec 1, 2025, 00:00

  • EE755 When Cost-Effectiveness No Longer Counts: Industry Views on the Undermining of HTA Principles in Korea

    Dec 1, 2025, 00:00

  • CO60 Comparative Real-World Effectiveness of Tyrosine Kinase Inhibitors as Induction Therapy for Philadelphia-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study

    Dec 1, 2025, 00:00

  • RWD93 Healthcare Resource Utilization Before and After Cardiovascular Disease Diagnosis in the NHS: A Descriptive Cohort Study

    Dec 1, 2025, 00:00

  • HPR208 The Landscape of Antibiotic Development and Regulation in the United States and Europe, Alongside Evolving Industry Incentive Strategies

    Dec 1, 2025, 00:00

  • EPH46 Clinical Functional Profile and Neuroimaging in Cerebral Palsy: A Population-Based Study

    Dec 1, 2025, 00:00

  • PT8 Does Proposed IRP Introduction in the US Align With Current IRP Trends and With Best Practice Guidelines?

    Dec 1, 2025, 00:00

  • CO35 Burden of Illness Among Patients With Transfusion Dependent Beta-Thalassemia in Spain: A Registry-Based Study

    Dec 1, 2025, 00:00

  • EE743 Unlocking the Value of RSV Adult Vaccination With Adjuvanted RSVpreF3 Vaccine in Spain: A Return on Investment Analysis Using an Integrated Actuarial Macroeconomic Model

    Dec 1, 2025, 00:00

  • MSR133 Integrating Equity and Efficiency in Health Economic Evaluation: Development of Equity-Informed Methodologies in the French Healthcare Context (INEES Project)

    Dec 1, 2025, 00:00

  • EE640 Real-World–Based Cost-Effectiveness of Lipid-Lowering Therapies for ASCVD Patients With High CV Risk in Taiwan

    Dec 1, 2025, 00:00

  • CO201 Real-World Clinical and Economic Outcomes of Time in Range in Association With Diabetic Retinopathy Among Patients With Type I Diabetes

    Dec 1, 2025, 00:00

  • EE569 Long-Term Impact of Emicizumab in Hemophilia A (HA): Analysis by Inhibitor Status in Three Latin American (LATAM) Countries

    Dec 1, 2025, 00:00

  • EE384 Economic Evaluation of Sodium Zirconium Cyclosilicate Lokelma for Treating Hyperkalemia in Patients With Heart Failure and/or Chronic Kidney Disease in Egypt

    Dec 1, 2025, 00:00

  • CO220 Subtyping Atopic Dermatitis Trajectories Using Digital Patient-Reported Outcomes and Machine Learning

    Dec 1, 2025, 00:00

  • EE73 Bimekizumab Budget Impact Analysis for the Treatment of Patients With Moderate-to-Severe Hidradenitis Suppurativa (HS) in Greece

    Dec 1, 2025, 00:00

  • RWD112 Landscape of Data Sources for Real-World Observational Studies: Focus on the French Context

    Dec 1, 2025, 00:00

  • EE731 Therapeutic Drug Monitoring and Selective Use of Glucarpidase in High-Dose Methotrexate Therapy: A Cost Analysis From the Algerian Payer Perspective

    Dec 1, 2025, 00:00

  • HPR51 Comparison of the Early Access and Postmarket Evaluation Systems in South Korea and Germany’s DIGA

    Dec 1, 2025, 00:00

  • RWD95 Healthcare Resource Utilization in Adults with Type 1 Diabetes Who Have a Prior Type 2 Diabetes Misdiagnosis and Recorded HbA1c in a US Managed Care Population

    Dec 1, 2025, 00:00

  • EE693 The Cost-Effectiveness of Imlifidase Idefirix® for Desensitization Treatment of Highly Sensitized Adult Kidney Transplant Patients in Ireland

    Dec 1, 2025, 00:00

  • PCR144 Investigation of the Impact of Hereditary Angioedema (HAE) on Health-Related Quality of Life: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • EE96 Budget Impact Analysis of STRIDE (Tremelimumab + Durvalumab) vs. Atezolizumab + Bevacizumab for Unresectable Hepatocellular Carcinoma: Qatari Payer and Societal Perspectives

    Dec 1, 2025, 00:00

  • EE217 Cost-Effectiveness Analysis of Quizartinib for Adult Patients With Newly Diagnosed FLT3-ITD+ Acute Myeloid Leukemia (AML) in Spain

    Dec 1, 2025, 00:00

  • RWD85 FLAME: An Open-Source Federated Platform for Deeply Phenotyped and Multimodal Studies at Population Scale

    Dec 1, 2025, 00:00

  • MSR84 Empirical Comparison of Four Approaches for Generating Confidence Intervals Around Weighted Trial-Level Correlation

    Dec 1, 2025, 00:00

  • HPR58 Distributional Cost-Effectiveness Analysis: A Case Study of Obesity

    Dec 1, 2025, 00:00

  • MSR167 Piloting a GenAI Agent for Structured Quality Appraisal of Network Meta-Analyses Using the ISPOR-AMCP-NPC Checklist

    Dec 1, 2025, 00:00

  • EE709 The Growing Importance of Reserve Antibiotics in Organ Transplant Care and the Role of Timely Appropriate Antibiotic Treatment to Preserve the Benefits of Prior Health Investments

    Dec 1, 2025, 00:00

  • CO231 Systematic Review of Prognostic Factors for Efficacy and Safety Outcomes in CAR-T Cell Therapy for Diffuse Large B-cell Lymphoma

    Dec 1, 2025, 00:00

  • MSR3 A Generalizable Discrete Event Simulation Framework to Assess Clinical and Economic Impact of Prescription Protocol Revisions

    Dec 1, 2025, 00:00

  • HPR82 Evolution of Negotiations and Contracts for Reimbursement of Pharmaceuticals in Greece Between 2020 and 2025: Onwards and Upwards

    Dec 1, 2025, 00:00

  • CO61 Comparison of Bispecific T-cell Engager Antibodies and CAR-T Therapies for Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma: A Systematic Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • RWD165 Real-World Treatment Patterns of Locally Advanced and Metastatic Urothelial Cancer (la/MUC) in Fran A Secondary Database Analysis

    Dec 1, 2025, 00:00

  • EPH174 Out-of-Work Transitions in the European Population With Noncommunicable Diseases

    Dec 1, 2025, 00:00

  • MSR77 Differential Responsiveness and Minimally Important Difference of EQ-5D: Truth or Artifact?

    Dec 1, 2025, 00:00

  • HPR233 Using Expert Consensus to Expand Access in Rare Disease Populations: Generating Evidence for Patients With Permanently Ventilated Spinal Muscular Atrophy

    Dec 1, 2025, 00:00

  • HTA180 How Societal Is Sweden? A Study of Inclusion of Societal Costs in Swedish Reimbursement Decisions

    Dec 1, 2025, 00:00

  • CO200 Real-World Pharmacovigilance of Metoprolol: A Disproportionality Analysis of Adverse Events Using US FDA Adverse Event Reporting System (FAERS) and Bioinformatics

    Dec 1, 2025, 00:00

  • HTA257 Non-Proportional Hazards Network Meta-Analysis in NICE Technology Appraisals Prevalence and Insights

    Dec 1, 2025, 00:00

  • HPR224 Trends and Scope of Japan’s Across-the-Board Pharmaceutical Price Revisions in FY2021-25

    Dec 1, 2025, 00:00

  • HPR30 Assessing the Potential Impact of NICE’s Updated HST Routing Criteria on Ultraorphan Drugs

    Dec 1, 2025, 00:00

  • HSD20 Care Dependency and Sick Leave Patterns in Early Alzheimer's Disease: A Retrospective Claims Data Analysis in Germany

    Dec 1, 2025, 00:00

  • CO181 Positioning of the Eluvia™, Drug-Eluting Stent in the Treatment of Peripheral Artery Disease (PAD) in Türkiye: Insights From a Specialist Panel Survey and Focus Group Study

    Dec 1, 2025, 00:00

  • EE233 Cost-Effectiveness of Adjuvant Alectinib vs. Platinum-Based Chemotherapy in Resected Stage IB-IIIA ALK-Positive NSCLC: A French Health Economic Evaluation

    Dec 1, 2025, 00:00

  • HPR192 Ten Years of Portugal’s HTA System Through Stakeholder Eyes: Reflections and Future Priorities

    Dec 1, 2025, 00:00

  • HTA270 Potential Implications of EU Joint Clinical Assessment (JCA) for the UK Affiliate of a Global Pharmaceutical Company

    Dec 1, 2025, 00:00

  • HPR106 Gender-specific Drug Prices in Germany: A Comparative Analysis

    Dec 1, 2025, 00:00

  • MSR48 Bootstrap Methods for Confidence Interval Estimation in Small Samples: Implications for Health Economics

    Dec 1, 2025, 00:00

  • RWD113 Landscape of Natural Language Processing (NLP) Capabilities at Clinical Sites: Insights From a Real-World (RW) Gastric Cancer (GC) Study

    Dec 1, 2025, 00:00

  • HPR114 How Health Policy Influences HTA Outcomes: Comparative Insights From Ukraine, Moldova, and Bulgaria

    Dec 1, 2025, 00:00

  • CO44 Clinical Effectiveness and Safety of Second-Line Therapies for Immune Thrombocytopenia (ITP): A Systematic Literature Review

    Dec 1, 2025, 00:00

  • HSD82 Patient Blood Management Efficiency in Patients Subject to Orthopedic and Oncologic Elective Surgery

    Dec 1, 2025, 00:00

  • HTA145 Exploring Methodologies for Defining and Modeling Cure in Melanoma: Impacts on Estimating Cure Metrics

    Dec 1, 2025, 00:00

  • EE115 Budgetary Impact of Generalized Pustular Psoriasis (GPP) in the Brazilian Private Healthcare System: A Real-World Data Analysis

    Dec 1, 2025, 00:00

  • CO255 Treatments for Children With Newly Diagnosed Medulloblastoma: A Systematic Review Of Randomized Controlled Trials

    Dec 1, 2025, 00:00

  • PCR209 Relevance of Quality Indicators for Supporting Patients’ Choice of Hospitals: An Online Survey

    Dec 1, 2025, 00:00

  • EE84 Budget Impact Analysis of Eplerenone For the Management of Heart Failure With Reduced Ejection Fraction (HFrEF) in Italy

    Dec 1, 2025, 00:00

  • PCR57 Describing the Burden of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) on Patients and Their Caregivers: A Real-World Survey in Europe, the United States, and Japan

    Dec 1, 2025, 00:00

  • EE528 Impact of Comparator Type on Cost-Effectiveness Outcomes: Insights From ASMR III Evaluations in France

    Dec 1, 2025, 00:00

  • RWD53 Decoding Asthma: A Tale of Two Databases

    Dec 1, 2025, 00:00

  • EE70 Avacopan in the Treatment of ANCA-Associated Vasculitis: A Cost-Utility Analysis in Portugal

    Dec 1, 2025, 00:00

  • CO25 Baseline Characteristics and Treatment Persistence in UK Patients With Moderate-to-Severe UC Following 12-Week Mirikizumab Induction: Real-World Data From IBD BioResource

    Dec 1, 2025, 00:00

  • EPH127 Hospital Mortality in Germany Analysis of German Hospital Data From 2000 to 2019

    Dec 1, 2025, 00:00

  • EE446 Evaluating the Performance of an Artificial Intelligence A-Powered Tool for Assessing Quality of Published Economic Evaluations: A Comparison With Human Reviewers Using the Drummond Checklist

    Dec 1, 2025, 00:00

  • SA43 From Methods to Decisions: A Transparent Framework for Population-Adjusted Treatment Comparisons

    Dec 1, 2025, 00:00

  • SA80 Real-World Cancer Treatments for Common Solid Tumors in China: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • CO178 Pegunigalsidase Alfa Elfabrio® as a Long-Term Enzyme Replacement Therapy in Adults With Fabry Disease: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • HPR162 Predicting the Maximum Fair Price (MFP) From Medicare Negotiations

    Dec 1, 2025, 00:00

  • HTA248 Navigating Reimbursement Challenges for Pharmacological Interventions in Celiac Disease: Lessons From Analogous Conditions

    Dec 1, 2025, 00:00

  • EPH227 The Association Between Generalized Anxiety Disorder Symptom Severity and Comorbid Health Conditions Among the US General Adult Population

    Dec 1, 2025, 00:00

  • EPH162 Modeling the Long-Term Bone Health Impact of TDF/FTC PrEP in Adolescent MSM

    Dec 1, 2025, 00:00

  • HTA119 Early Systematic PICO Scenario Identification and Prioritization for EU HTA Joint Clinical Assessments

    Dec 1, 2025, 00:00

  • EE510 Healthcare Resource Utilization Among Adults With Pneumococcal Disease in England 2017-2022: A Retrospective Database Analysis

    Dec 1, 2025, 00:00

  • PCR259 Using Social Media Listening to Understand Oncology-Specific Patient Experiences: A Comparison of Pharmaceutical Industry-Funded vs. Nonpharmaceutical Industry-Funded Studies

    Dec 1, 2025, 00:00

  • EPH34 Burden of Hospitalized Viral Respiratory Infections in Fran Insights From the 2022-2023 Season

    Dec 1, 2025, 00:00

  • MSR225 Win Ratio in the Presence of Censored Data: Can Probabilistic Variants Improve Robustness?

    Dec 1, 2025, 00:00

  • MSR177 Qualitative Analysis of Results From a Delphi Study to Formalize a Treatment Protocol for Children With Early Diagnosed Duchenne Muscular Disease (DMD) Using Giles®, an Artificial Intelligence Agent for Healthcare Research

    Dec 1, 2025, 00:00

  • MSR206 Transporting Treatment Effects for Survival Outcomes Under Informative Censoring: A Simulation Study Using Summary-Level Data in the Target Population

    Dec 1, 2025, 00:00

  • EE341 Does Insurance Value in Metastatic Breast Cancer Vary by Age Testing for Variation in Willingness to Pay for Novel Treatments Among Women in the US?

    Dec 1, 2025, 00:00

  • EE408 Embracing the Long-Term in Disruptive Health Innovations: A Strategic Necessity or a Necessary Evil? Cost Utility of Langerhans Islet Grafting in Unstable Type 1 Diabetes

    Dec 1, 2025, 00:00

  • HTA218 Lessons Learnt From PICO Exercise Developed by the Joint Clinical Assessment Subgroup for Etranacogene Dezaparvovec

    Dec 1, 2025, 00:00

  • EE68 Assessment of the Cost Utility of Palivizumab for Preventing Severe Respiratory Syncytial Virus (RSV) Infection in Preterm Infants Born 29-35 Weeks' Gestational Age in the Philippines

    Dec 1, 2025, 00:00

  • MT12 Cost Impact of the Porcine Urinary Bladder Matrix in Patients With Diabetic Foot Ulcer in the United Kingdom

    Dec 1, 2025, 00:00

  • CO237 The Clinical Burden of Fractures in Osteogenesis Imperfecta: A Systematic Review

    Dec 1, 2025, 00:00

  • EE237 Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Stabilized Prefusion F Subunit Vaccine (RSVpreF) Among Older Adults in Ireland

    Dec 1, 2025, 00:00

  • EE577 Methodological Challenges for the Economic Evaluation of Genomic Newborn Screening: A Scoping Review

    Dec 1, 2025, 00:00

  • HTA162 German HTA Outcomes for Rare Disease Drugs When Orphan Designation Does Not Legally Determine Added Benefit

    Dec 1, 2025, 00:00

  • RWD154 Real-World Evidence in European Orphan Drug Submissions and the Impact on Reimbursement Success

    Dec 1, 2025, 00:00

  • HTA173 Health Technology Assessment (HTA) Systems and Risk Identification Strategies: A Comparative Analysis Across Western European Countries, Canada, and Australia

    Dec 1, 2025, 00:00

  • CO8 An Adjusted Indirect Comparison of Once-Weekly Insulin Efsitora Alfa vs. Insulin Icodec for Adults With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin

    Dec 1, 2025, 00:00

  • EPH121 Healthcare Resource Use in Transthyretin Amyloidosis Cardiomyopathy: An Observational Study in the UK Clinical Setting Using Electronic Health Records

    Dec 1, 2025, 00:00

  • MSR126 Identifying Risk Profiles for Early Treatment Discontinuation in Geographic Atrophy Using Machine Learning and SHAP Clustering

    Dec 1, 2025, 00:00

  • EE34 A Systematic Literature Review on Costs and Healthcare Resource Utilization in Spinal Muscular Atrophy

    Dec 1, 2025, 00:00

  • PCR88 Explaining Psychiatric Comorbidities in Patients With Skin Conditions: The Importance of Clinical Characteristics and Patient-Reported Disease Impact

    Dec 1, 2025, 00:00

  • CO62 Comparison of Persistence Rates: Tildrakizumab vs. Adalimumab/Ustekinumab Based on a German Longitudinal Prescription Database (LRx) of Social Health Insurance Patients in Outpatient Care

    Dec 1, 2025, 00:00

  • EE542 Impact of SGLT2-Inhibitor Uptake in CKD Management in Denmark: A Decision Economic Model

    Dec 1, 2025, 00:00

  • P46 Eliciting Preferences for Combination Vaccines Protecting Against Multiple Respiratory Viruses: A Cross-Sectional Discrete Choice Experiment of Adults Aged 50 in the US

    Dec 1, 2025, 00:00

  • EPH159 Mapping of Treatment Patterns and Transfusion Status in Danish and Swedish Myelofibrosis (MF) Patients

    Dec 1, 2025, 00:00

  • RWD38 Comparative Analysis of Safety of Targeted NSCLC Therapies Using the FDA Adverse Event Reporting System (FAERS) Differing Experience of Healthcare Providers (HCP) From EU vs. US

    Dec 1, 2025, 00:00

  • EE259 Cost-Effectiveness of Minocycline Intravenous for the Treatment of Serious Infections Due to Multidrug-Resistant Acinetobacter baumannii in Jordan

    Dec 1, 2025, 00:00

  • MSR141 Machine Learning for Missing Data Imputation in Healthcare Research: A Systematic Review of Methods and Applications

    Dec 1, 2025, 00:00

  • PCR121 Health-Related Quality of Life of Patients With Epidermolysis Bullosa in Hungary: Results With the EQ-5D-5L and EQ-5D-Y-3L Preference-Based Measurement Tools

    Dec 1, 2025, 00:00

  • PCR189 Predicting Italian EQ-5D-3L Health State Utilities From UK Values: Validation of a Nonlinear Utility Adjustment Model Using Real-World Evidence

    Dec 1, 2025, 00:00

  • HSD17 Burden of Healthcare Waste for European Hospitals: Findings From an AI-Based Literature Research

    Dec 1, 2025, 00:00

  • HPR132 Leveling the Field: How the MFN Could Transform Drug Pricing

    Dec 1, 2025, 00:00

  • EPH205 Real-World Treatment Patterns of Trofinetide in Rett Syndrome: Analysis of Medical Pharmacy-Linked Claims Database in the United States

    Dec 1, 2025, 00:00

  • HPR83 Evolution of Pharmaceutical Pricing and Reimbursement Agreements in Spain Over the Last 10 Years: Towards an Outcomes-Based Approach

    Dec 1, 2025, 00:00

  • PCR244 The Use of Patient-Reported Experience Measures in Adults With Obstructive Sleep Apnea: A Systematic Evidence Review

    Dec 1, 2025, 00:00

  • EE31 A Review of Indirect Costs Within Economic Appraisals in France

    Dec 1, 2025, 00:00

  • RWD185 Trends and Disparities in Prostate Cancer Incidence Prevalence and Survival: A SEER Analysis 2000-2022

    Dec 1, 2025, 00:00

  • RWD159 Real-World Insights Into Breast Cancer in the UK: Findings From UK EHR-Derived Data

    Dec 1, 2025, 00:00

  • EPH280 Years of Life Lost and Productivity TB1 SY2 Costs Due to Premature Cancer-Related Mortality in Morocco

    Dec 1, 2025, 00:00

  • CO260 Using Natural Language Processing to Identify Sequencing Patterns in Advanced Urothelial Carcinoma: A Real-World Observational Study

    Dec 1, 2025, 00:00

  • MSR95 Evaluating the Performance of a Supervised Artificial Intelligence Model in Screening Abstracts for Oncology-Focused Targeted Literature Reviews

    Dec 1, 2025, 00:00

  • SA68 Methodology and Challenges of Network Meta-Analysis in Health Technology Assessment of Medical Devices: A Case Study of Drug-Eluting Stents

    Dec 1, 2025, 00:00

  • HPR190 Staying Competitive in a Crowded Vaccine Market: Is There Room for a Third or Fourth Entrant in the Same Disease Area?

    Dec 1, 2025, 00:00

  • RWD143 Real-World Healthcare Resource Utilization and Related Costs Associated With Lung Cancer in the Brazilian Private Market

    Dec 1, 2025, 00:00

  • EE106 Budget Impact of Implementing a Case-Finding Program in UK Patients at High Risk for COPD to Explore Cost Savings Due to Earlier Diagnosis

    Dec 1, 2025, 00:00

  • HTA279 Reassessing NICE's Highly Specialized Technologies (HST) Criteria: A Retrospective Review of Borderline and Approved Appraisals Under the Revised Framework

    Dec 1, 2025, 00:00

  • Table of Contents

    Dec 1, 2025, 00:00

  • EE249 Cost-Effectiveness of Etrasimod, Ozanimod, and Adalimumab Compared to Infliximab in Treatment-Naive Patients With Moderate to Severe Ulcerative Colitis

    Dec 1, 2025, 00:00

  • EPH99 Examining Knowledge Regarding Needlestick Injuries Among Students in Higher Healthcare Education

    Dec 1, 2025, 00:00

  • RWD104 Incidence of Intracerebral Hemorrhage in Patients With Mild Cognitive Impairment or Alzheimer’s Dementia in United States Veterans

    Dec 1, 2025, 00:00

  • EE139 Comparative Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole for the Treatment of Invasive Aspergillosis in Algerian Hospital Setting

    Dec 1, 2025, 00:00

  • EE711 The Impact of Adherence on the Value Assessment of Cardiovascular Interventions: A Systematic Literature Review of Economic Evaluations

    Dec 1, 2025, 00:00

  • MT47 Variation in Revisions and Complications After Proximal Femoral Fracture Fixation—Association With Provider Characteristics

    Dec 1, 2025, 00:00

  • EPH202 Quantifying the Economic Burden of Undiagnosed Sleep Apnea in India’s Productive Population: A Health Economic Modeling Approach

    Dec 1, 2025, 00:00

  • PCR79 Evaluating GenAI vs. Human Screenshot Review Outputs in eCOA Localization: Does AI Hold the Key to Improved Feedback?

    Dec 1, 2025, 00:00

  • HTA33 Analysis of the Implementation of Additive PICOs in a European Joint Health Technology Assessment Implications of EUHTA for Pharma: A Qualitative Exploration

    Dec 1, 2025, 00:00

  • EE205 Cost-Effectiveness Analysis of Inhaled Levodopa for Managing OFF Episodes in Patients With Parkinson’s Disease

    Dec 1, 2025, 00:00

  • EPH150 Is Europe and European Evidence Development an Afterthought in Pharmaceutical Early Stage Development Decisions? An Exploratory Qualitative Survey

    Dec 1, 2025, 00:00

  • HTA78 Comparative Analysis of Reimbursement Landscapes: Advantages and Challenges of Bispecifics vs. CAR-T Therapies

    Dec 1, 2025, 00:00

  • CO85 Effectiveness of Inclisiran and Evolocumab in LDL-C Goal Attainment: A Hybrid Decision Tree-Markov Model Analysis

    Dec 1, 2025, 00:00

  • EPH279 Years of Life Lost and Productivity Costs Due to Premature Cancer-Related Mortality in Ukraine and in Kiev City, Lviv, and Cherkasy Regions

    Dec 1, 2025, 00:00

  • MT28 Impact of RFID-Enabled Unit-Level Traceability on Resource Utilization and Quality Assurance in Prefilled Syringe Production

    Dec 1, 2025, 00:00

  • HTA201 Influence of NICE Real-World Evidence Framework on HTA Submissions: Sensitivity Analyses in Real-World External Control Arm Studies

    Dec 1, 2025, 00:00

  • HTA345 Uncertainty About How to Translate JCA Into National HTA Submissions (EU-4 and Poland): A Systematic Comparison From an Industry Perspective

    Dec 1, 2025, 00:00

  • HTA166 Guidance for Real-World Evidence Generation for the Joint Clinical Assessment Process and Its Implications for Country-Specific HTA Body Acceptability

    Dec 1, 2025, 00:00

  • SA82 Real-World Findings From the Provent Study of Dupilumab Therapy for Severe Asthma: 2-Year Analysis

    Dec 1, 2025, 00:00

  • MSR209 Understanding Drivers on Healthcare Resource Utilization Costs Among People Living With Obesity in UK Clinical Practice

    Dec 1, 2025, 00:00

  • HTA96 Cost-Effectiveness Assessment of Orphan Drugs in Fran Key Insights from CEESP Reviews (2021-2024)

    Dec 1, 2025, 00:00

  • EE167 Cost-Effectiveness of a Digital Health Intervention for Screening and Managing Hypertension at Primary Care Level in Kenya: A Microsimulation Model

    Dec 1, 2025, 00:00

  • EE59 Assessing the Cost-Effectiveness of Semaglutide 24 mg in the Management of People With Obesity and Knee Osteoarthritis in the UK

    Dec 1, 2025, 00:00

  • EE669 Spillover Effect in Health Utility Values: A Systematic Review

    Dec 1, 2025, 00:00

  • MSR1 A Comparison of Methods for Missing Covariates in a Meta-Regression Using Data From a Systematic Review on Oral Epithelial Dysplasia

    Dec 1, 2025, 00:00

  • HTA39 Are We SEEing It Yet? The Use of Structured Expert Elicitation Protocols for Decision Making

    Dec 1, 2025, 00:00

  • SA14 Assessing the Use of Artificial Intelligence in Publication-Grade Research: A Literature Review of Applications in HEOR

    Dec 1, 2025, 00:00

  • HTA302 Statistical Analysis of Health Technology Assessment Outcomes in Oncology: An Analysis of Key Clinical Value Drivers in Germany and France

    Dec 1, 2025, 00:00

  • PCR263 Valuing Health States When Transitioning From Stage 2 to Stage 3 Type 1 Diabetes in a Sample of the General Population in the United Kingdom

    Dec 1, 2025, 00:00

  • EPH32 Budget Impact of an Organized Screening Program for Chronic Kidney Disease in High-Risk Populations in France

    Dec 1, 2025, 00:00

  • SA22 Confirmation of Diagnosis Method for Robust Participant Selection in Direct-to-Patient Real-World Evidence Studies

    Dec 1, 2025, 00:00

  • EE600 Optimizing Colorectal Cancer Screening in the Czech Republic: Cost-Effectiveness of Lowering the Starting Age to 45 and Introducing an Upper Limit

    Dec 1, 2025, 00:00

  • HPR88 External Reference Pricing (ERP) Availability vs. Reimbursement Timelines in Poland and Other European Countries: The Analysis of EURIPID Database

    Dec 1, 2025, 00:00

  • EPH62 Diabetes Trends in France (2021-2023): A Descriptive Study Based on the THIN Database

    Dec 1, 2025, 00:00

  • EPH148 Insights From a French Postmarketing Authorization Early Access (MA EA) Mechanism: Projecting Clinical and Economic Benefits of Neoadjuvant Nivolumab–Platinum-Based Chemotherapy (PDC) in Resectable Non-Small Cell Lung Cancer

    Dec 1, 2025, 00:00

  • EE121 Cardiovascular Disease Risk-Reducing Strategies in Qatari Diabetes Patients: A Cost-Effectiveness Study

    Dec 1, 2025, 00:00

  • EPH82 Epidemiology of Diabetes Mellitus in Pregnancy in Hungary: Trends and Future Projections

    Dec 1, 2025, 00:00

  • HTA280 Reassessment of Orphan Drugs in Germany After Exceeding the Annual Sales Limit of €30 Million: Impact on the Reimbursement Price and Key Influencing Factors

    Dec 1, 2025, 00:00

  • Understanding the Role of Clinical and Functional Needs in Home-Visit Nursing Effectiveness: Evidence From South Korea

    Dec 1, 2025, 00:00

  • HPR60 Diverging Impacts of Evergreening and Biosimilars on Trastuzumab Utilization and Costs in South Korea: Implications for Sustainable Access and Market Competition

    Dec 1, 2025, 00:00

  • EE574 Measures for Integrating Carbon Footprints Into Economic Evaluations: A Targeted Review of Environmental and Economic Metrics

    Dec 1, 2025, 00:00

  • EE310 Cost-Utility Analysis of the BCIS Conveyance Algorithm for Out-of-Hospital Cardiac Arrest Patients

    Dec 1, 2025, 00:00

  • CO123 Fezolinetant Veoza™ As a Nonhormonal Treatment for Moderate to Severe Vasomotor Symptoms in Postmenopausal Women: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • EE349 Economic and Antibiotic Benefits of Vonoprazan-Based Regimens for First-Line Helicobacter Pylori Eradication in China

    Dec 1, 2025, 00:00

  • MT9 Clinical Outcomes of Early Diagnosis of Infections of Sterile Body Fluids: A Living Systematic Review and Meta Analysis

    Dec 1, 2025, 00:00

  • HTA321 The Interim Acceptance and Ultraorphan Pathways in Scotland: An Update

    Dec 1, 2025, 00:00

  • RWD156 Real-World Evidence Study on Healthcare Resource Utilization (HCRU) Among Cancer Patients in the Helsinki and Uusimaa (HUS) Region, Finland

    Dec 1, 2025, 00:00

  • EE176 Cost Of Adverse Events Associates With the Management of Invasive Mold Disease With Isavuconazole Compared With Voriconazole in Spain

    Dec 1, 2025, 00:00

  • EPH216 Social Inequality in the Uptake of Varicella Vaccination: A Danish Nationwide Observational Study

    Dec 1, 2025, 00:00

  • MSR37 Artificial Intelligence-Powered Literature Reviews (AILRs): Streamlining Joint Clinical Assessment (JCA) Dossier Preparation for the Next Generation of Pharmaceutical Submissions

    Dec 1, 2025, 00:00

  • CO111 Evaluating Therapeutic Landscape in Radio-Iodine-Refractory–Differentiated Thyroid Cancer (DTC): A Bayesian Network Meta-Analysis of Clinical Efficacy

    Dec 1, 2025, 00:00

  • EE67 Assessment of Health State Utilities Associated With Treatment for Chronic Hepatitis B Virus (HBV) Infection

    Dec 1, 2025, 00:00

  • PCR190 Predicting Self-Efficacy in Managing Type 2 Diabetes: Results From a Low-Income, Less Educated Community of Quetta City, Pakistan

    Dec 1, 2025, 00:00

  • EE431 Evaluating Cost-Consequences and Digital Transformation Through Concentric Consent: An Impact Assessment at Oxford University Hospitals NHS Foundation Trust

    Dec 1, 2025, 00:00

  • EPH80 Epidemiology and Outcomes in a Linked Cohort of Cancer Pathology and Electronic Medical Records From the PHARMO Data Network

    Dec 1, 2025, 00:00

  • EPH81 Epidemiology of Breast Cancer in France

    Dec 1, 2025, 00:00

  • PCR81 Evaluating Patient Preferences for Clinical Trial Endpoints in Early Stage Cancer: A Discrete Choice Experiment in Canada

    Dec 1, 2025, 00:00

  • EE637 Real-World Healthcare Resource Utilization and Costs by Glycemic Control in People With Type 2 Diabetes: An Observational Population-based Register Study in Sweden

    Dec 1, 2025, 00:00

  • EPH107 Exploring the Impact of Dupilimab on the Patient Care Pathways: GHG Emissions of Patients With Moderate-to-Severe COPD In France

    Dec 1, 2025, 00:00

  • EE8 A Cost per Responder Analysis of Lipid-Lowering Therapies in Patients With Established Atherosclerotic Cardiovascular Disease in Italy

    Dec 1, 2025, 00:00

  • EE638 Real-World Healthcare Resource Utilization in Individuals With Phenylketonuria: A Retrospective Observational Study in the United States

    Dec 1, 2025, 00:00

  • RWD69 Economic and Clinical Insights Into Oral Nutritional Supplementation in Oncology: A Brazilian Real-World Study

    Dec 1, 2025, 00:00

  • PCR257 Uptake and Early Removal of Hormonal Implant Contraceptive Among Women Attending the Family Planning Clinic in a Tertiary Institution in West Africa January 2018-December 2020

    Dec 1, 2025, 00:00

  • HPR95 Financial Impact of EU MDR Complian A Cost-Mapping Assessment for Manufacturers

    Dec 1, 2025, 00:00

  • EE368 Economic Burden Utilities and Cost-Effectiveness of the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • EE713 The Impact of Delaying Access to Innovative Therapies in Emerging Markets for Chronic Lymphocytic Leukemia: A Modeling Study

    Dec 1, 2025, 00:00

  • HTA86 Comprehensive Clinical Evaluation of Amphotericin B in the Treatment of Invasive Fungal Disease in China

    Dec 1, 2025, 00:00

  • RWD161 Real-World Insights Into Prostate Cancer Management Using Electronic Health Record-Derived Data From the UK

    Dec 1, 2025, 00:00

  • MSR51 Can an Ensemble Machine-Learning Approach Outperform Traditional Models While Enhancing Accuracy, Fairness, and Interpretability in Clinical Risk Prediction?

    Dec 1, 2025, 00:00

  • RWD181 The Use of Oligometastatic Disease in Routine Radiology Practi A Real-World Data Analysis

    Dec 1, 2025, 00:00

  • MSR217 Using Propensity Weighting Methods With Real-World Data and Noncontrolled Extension Data From a Clinical Trial to Estimate Long-Term Treatment Effect: An Example in Alzheimer’s Disease

    Dec 1, 2025, 00:00

  • MSR220 What About a Latent Cure Model? Assessing Cure Models’ Performance in Pediatric Acute Lymphoblastic Leukemia Treated With Tisagenlecleucel

    Dec 1, 2025, 00:00

  • HSD10 Assessing the Quality and Determinants of Referrals From General Practitioners (Primary Care Physicians for Adults) to Specialist Physicians in the Cyprus Healthcare System

    Dec 1, 2025, 00:00

  • EPH90 Estimation of HER2-Negative Metastatic Breast Cancer Population Eligible for Innovative Treatments in France

    Dec 1, 2025, 00:00

  • MSR215 Using Machine Learning to Enable Timely Postpartum Care by Reliably Detecting Deliveries

    Dec 1, 2025, 00:00

  • HPR215 The Value of Medical Spending in China, 1991-2019

    Dec 1, 2025, 00:00

  • RWD25 Best Practices Framework for Real-World Data (RWD) in Regulatory Submissions

    Dec 1, 2025, 00:00

  • HSD124 Variations in Screening and Medication Takeup Rates for Alzheimer’s Disease

    Dec 1, 2025, 00:00

  • EE78 Broader Economic Effects of Investment in Cancer Control in Commonwealth Countries

    Dec 1, 2025, 00:00

  • HTA114 Diverging Health Technology Assessment Outcomes Between SMC and HAS: A Focus on the Role of Indirect Treatment Comparisons

    Dec 1, 2025, 00:00

  • HTA336 The Value Flower in Bloom: Emerging Recognition of Uncaptured Benefits in NICE HTA Decisions

    Dec 1, 2025, 00:00

  • CO139 Impact of Pharmacist-Led Interventions on Health-Related Quality of Life in Diabetic Patients: Assessment Using EQ-5D Domains and Visual Analog Scale

    Dec 1, 2025, 00:00

  • MSR137 Leveraging NLP to Characterize Real-World Triptan Use and Adherence From Unstructured EHR

    Dec 1, 2025, 00:00

  • RWD186 Trends of Prescriptions for Medical Technologies Not Covered by the Colombian Health Benefits Package Between 2020 and 2024: A Descriptive Study

    Dec 1, 2025, 00:00

  • RWD29 Characteristics of Real-World Data Landscape in Italy: A Scoping Review

    Dec 1, 2025, 00:00

  • EPH117 Group A Streptococcal Infections—Diagnostic Approaches and Antibiotics Prescriptions in Children and Adolescents in Germany: A Nationwide Representative Claims Data Analysis

    Dec 1, 2025, 00:00

  • HSD97 Real-World Treatment Patterns Among Patients With Relapsed or Refractory (R/R) NPM1 Mutated (NPM1m) Acute Myeloid Leukemia (AML) in the United States (US)

    Dec 1, 2025, 00:00

  • EPH237 The Health Impact of Pembrolizumab for the First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC) That Expresses High Levels of PD-L1 in Türkiye

    Dec 1, 2025, 00:00

  • EPH60 Development of a Markov Model-Based Visualization Tool of Regional HPV Vaccination Coverage Rates Over Time in Austria: Combining Data From Pharmaceutical Industry and Healthcare Data Including National Vaccination Registry

    Dec 1, 2025, 00:00

  • PCR194 Protocol for a Health Preference Study on Digital Health Interventions: Integrating DCE and BWS to Capture Subject, Interaction, System, and Societal Value

    Dec 1, 2025, 00:00

  • EE348 Early Stage Health Economic Evaluation of IMMUTOL Gene Therapy for Relapsing/Remitting Multiple Sclerosis in the Netherlands

    Dec 1, 2025, 00:00
  • 1
  • 2
  • 3
  • 4 (current)
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • »